[go: up one dir, main page]

ATE548381T1 - Modifizierte erythropoietin (epo)-polypeptide mit erhöhter proteaseresistenz und pharmazeutische zusammensetzungen daraus - Google Patents

Modifizierte erythropoietin (epo)-polypeptide mit erhöhter proteaseresistenz und pharmazeutische zusammensetzungen daraus

Info

Publication number
ATE548381T1
ATE548381T1 AT09765524T AT09765524T ATE548381T1 AT E548381 T1 ATE548381 T1 AT E548381T1 AT 09765524 T AT09765524 T AT 09765524T AT 09765524 T AT09765524 T AT 09765524T AT E548381 T1 ATE548381 T1 AT E548381T1
Authority
AT
Austria
Prior art keywords
polypeptides
epo
pharmaceutical compositions
protease resistance
modified
Prior art date
Application number
AT09765524T
Other languages
English (en)
Inventor
Thierry Guyon
Gilles Borrelly
Xavier Gallet
Lila Drittanti
Manuel Vega
Original Assignee
Hanall Biopharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hanall Biopharma Co Ltd filed Critical Hanall Biopharma Co Ltd
Application granted granted Critical
Publication of ATE548381T1 publication Critical patent/ATE548381T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/505—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
AT09765524T 2008-05-29 2009-05-29 Modifizierte erythropoietin (epo)-polypeptide mit erhöhter proteaseresistenz und pharmazeutische zusammensetzungen daraus ATE548381T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13037608P 2008-05-29 2008-05-29
PCT/EP2009/003862 WO2009152944A1 (en) 2008-05-29 2009-05-29 Modified erythropoietin (epo)polypeptides that exhibit increased protease resistance and pharmaceutical compositions thereof

Publications (1)

Publication Number Publication Date
ATE548381T1 true ATE548381T1 (de) 2012-03-15

Family

ID=40943614

Family Applications (1)

Application Number Title Priority Date Filing Date
AT09765524T ATE548381T1 (de) 2008-05-29 2009-05-29 Modifizierte erythropoietin (epo)-polypeptide mit erhöhter proteaseresistenz und pharmazeutische zusammensetzungen daraus

Country Status (7)

Country Link
US (1) US20120264686A9 (de)
EP (1) EP2297197B1 (de)
JP (1) JP2011520472A (de)
KR (1) KR101275950B1 (de)
CN (1) CN102186879A (de)
AT (1) ATE548381T1 (de)
WO (1) WO2009152944A1 (de)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60332358D1 (de) 2002-09-09 2010-06-10 Hanall Pharmaceutical Co Ltd Protease-resistente modifizierte interferon alpha polypeptide
US7998930B2 (en) 2004-11-04 2011-08-16 Hanall Biopharma Co., Ltd. Modified growth hormones
JP2010510794A (ja) 2006-11-28 2010-04-08 ハナル ファーマシューティカル カンパニー リミテッド 修飾型エリスロポエチンポリペプチド及びこの治療用用途
CA2780678A1 (en) 2009-11-19 2011-05-26 Ou Solis Biodyne Compositions for increasing polypeptide stability and activity, and related methods
US8822663B2 (en) 2010-08-06 2014-09-02 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
MX2013003681A (es) 2010-10-01 2013-11-20 Moderna Therapeutics Inc Ácidos nucleicos manipulados y métodos de uso de los mismos.
US9708379B2 (en) 2011-01-19 2017-07-18 The General Hospital Corporation Compositions for regulating iron homeostasis and methods of using same
JP2014511687A (ja) 2011-03-31 2014-05-19 モデルナ セラピューティクス インコーポレイテッド 工学操作された核酸の送達および製剤
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
EP2763701B1 (de) 2011-10-03 2018-12-19 Moderna Therapeutics, Inc. Modifizierte nukleoside, nukleotide und nukleinsäuren und verwendungen davon
CA3018046A1 (en) 2011-12-16 2013-06-20 Moderna Therapeutics, Inc. Modified nucleoside, nucleotide, and nucleic acid compositions
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
DE18200782T1 (de) 2012-04-02 2021-10-21 Modernatx, Inc. Modifizierte polynukleotide zur herstellung von proteinen im zusammenhang mit erkrankungen beim menschen
US10501512B2 (en) 2012-04-02 2019-12-10 Modernatx, Inc. Modified polynucleotides
JP6144355B2 (ja) 2012-11-26 2017-06-07 モデルナティエックス インコーポレイテッドＭｏｄｅｒｎａＴＸ，Ｉｎｃ． 化学修飾ｍＲＮＡ
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
BR112016007255A2 (pt) 2013-10-03 2017-09-12 Moderna Therapeutics Inc polinucleotídeos que codificam receptor de lipoproteína de baixa densidade
US9616114B1 (en) 2014-09-18 2017-04-11 David Gordon Bermudes Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
EP3194429A4 (de) * 2014-09-18 2018-06-13 Askgene Pharma, Inc. Neuartige feline erythropoietinrezeptor-agonisten
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
KR101947342B1 (ko) * 2017-05-05 2019-02-12 주식회사 유비프로틴 Gm-csf 반감기를 증가시키는 방법
CN107898812A (zh) * 2017-12-06 2018-04-13 广州瑞铂茵健康管理咨询有限公司 一种基于脐带干细胞及活性成分的软骨损伤混合修复液
CN110093336B (zh) * 2018-01-29 2023-03-24 上海雅心生物技术有限公司 一种稳定的胰蛋白酶及其制备方法
US12089930B2 (en) 2018-03-05 2024-09-17 Marquette University Method and apparatus for non-invasive hemoglobin level prediction
CN110241130B (zh) * 2018-03-09 2023-04-14 中国科学院分子植物科学卓越创新中心 控制植物粒数和粒重的gsn1基因、编码蛋白及其应用
AR113091A1 (es) * 2018-09-27 2020-01-22 Univ Nacional Del Litoral Eritropoyetina humana modificada
WO2021207611A1 (en) * 2020-04-09 2021-10-14 United States Government As Represented By The Department Of Veterans Affairs Compositions comprising recombinant epo and methods of use thereof
WO2021222806A1 (en) * 2020-05-01 2021-11-04 Icahn School Of Medicine At Mount Sinai Compositions and methods for preventing, detecting, and treating inflammatory bowel disease
EP3916008A1 (de) * 2020-05-26 2021-12-01 Sylus Co., Ltd. Neues peptid und verwendung davon zur behandlung von erkrankungen des gehirns und nervensystems
AU2021355358A1 (en) * 2020-09-30 2023-06-08 Realta Life Sciences, Inc. Peptides and methods of use
WO2022106888A2 (en) * 2020-11-18 2022-05-27 Chulabhorn Foundation Erythropoietin variants and uses thereof
WO2022159414A1 (en) 2021-01-22 2022-07-28 University Of Rochester Erythropoietin for gastroinfestinal dysfunction
WO2023222040A1 (zh) * 2022-05-17 2023-11-23 广州汉腾生物科技有限公司 重组促红细胞生成素及其应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH03151399A (ja) * 1989-11-07 1991-06-27 Snow Brand Milk Prod Co Ltd 変異ヒトエリスロポエチン
PA8536201A1 (es) * 2000-12-29 2002-08-29 Kenneth S Warren Inst Inc Protección y mejoramiento de células, tejidos y órganos que responden a la eritropoyetina
RU2003125654A (ru) * 2001-02-06 2005-03-10 Мерк Патент ГмбХ (DE) Модифицированный эритропоэтин (еро) с уменьшенной иммуногенностью
AU2002351746A1 (en) * 2001-12-21 2003-07-15 Maxygen Aps Erythropoietin conjugates
DE60332358D1 (de) 2002-09-09 2010-06-10 Hanall Pharmaceutical Co Ltd Protease-resistente modifizierte interferon alpha polypeptide
WO2004022747A1 (en) 2002-09-09 2004-03-18 Nautilus Biotech Rational directed protein evolution using two-dimensional rational mutagenesis scanning
US20060020396A1 (en) 2002-09-09 2006-01-26 Rene Gantier Rational directed protein evolution using two-dimensional rational mutagenesis scanning
US20050202438A1 (en) 2002-09-09 2005-09-15 Rene Gantier Rational directed protein evolution using two-dimensional rational mutagenesis scanning
CN100405906C (zh) * 2002-10-09 2008-07-30 尼奥斯技术有限公司 促红细胞生成素:促红细胞生成素的重构和糖缀合
US20040091961A1 (en) * 2002-11-08 2004-05-13 Evans Glen A. Enhanced variants of erythropoietin and methods of use
CA2563874A1 (en) * 2004-04-23 2005-11-03 Cambridge Antibody Technology Limited Erythropoietin protein variants
WO2006029094A2 (en) * 2004-09-02 2006-03-16 Xencor, Inc. Erythropoietin derivatives with altered immunogenicity
GB0500099D0 (en) * 2005-01-05 2005-02-09 Cambridge Antibody Tech Methods and means relating to protein variants
JP2010510794A (ja) * 2006-11-28 2010-04-08 ハナル ファーマシューティカル カンパニー リミテッド 修飾型エリスロポエチンポリペプチド及びこの治療用用途
US20080260820A1 (en) * 2007-04-19 2008-10-23 Gilles Borrelly Oral dosage formulations of protease-resistant polypeptides

Also Published As

Publication number Publication date
KR20110022638A (ko) 2011-03-07
KR101275950B1 (ko) 2013-06-25
CN102186879A (zh) 2011-09-14
US20120094906A1 (en) 2012-04-19
WO2009152944A1 (en) 2009-12-23
US20120264686A9 (en) 2012-10-18
EP2297197A1 (de) 2011-03-23
JP2011520472A (ja) 2011-07-21
EP2297197B1 (de) 2012-03-07

Similar Documents

Publication Publication Date Title
ATE548381T1 (de) Modifizierte erythropoietin (epo)-polypeptide mit erhöhter proteaseresistenz und pharmazeutische zusammensetzungen daraus
WO2008065372A3 (en) Modified erythropoietin polypeptides and uses thereof for treatment
EA201171220A1 (ru) Мутанты fgf21 и их применение
EA201001883A1 (ru) Мутанты fgf21 и их применение
WO2007110231A3 (en) MODIFIED INTERFERON-β (IFN-β) POLYPEPTIDES
BR112012017345A2 (pt) "composições e métodos de pgl para a produção aumentada de isopreno e outros produtos com 6-fosfogliconolactonase (pgl)"
MA32771B1 (fr) Mutants fgf21 et leurs utilisations
MX2011013903A (es) Polipeptidos quimericos y usos de los mismos.
CL2008000434A1 (es) Compuestos derivados de 2-amino-oxazolinas; proceso de obtencion; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como depresion, ansiedad, estres, trastorno bipolar, entre otros.
NO20082531L (no) Neuropilinantagonister
BR112014022708A8 (pt) uso de uma proteína ligante de neurotrofina p75ntr, uso de uma molécula de ácido nucleico, uso de um vetor de expressão replicável, célula hospedeira, composição farmacêutica e kit
EA201290964A1 (ru) Пептидные конъюгаты агонистов рецептора glp-1 и их применение
BR112013010857A2 (pt) imonoglubulinas de duplo domínio variável e usos das mesmas
CL2007003629A1 (es) Compuestos heterociclicos aril-sustituidos, moduladores del receptor de cannabinoides tipo i (cb1); proceso de preparacion; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como trastornos metabolicos y trastornos cognitivos.
WO2007133835A8 (en) Ras mutation and compositions and methods related thereto
CL2008000670A1 (es) Compuestos derivados de tiazolidindionas y oxazolidindionas sustituidas; composicion farmaceutica; proceso de preparacion de la composicion farmaceutica; y uso en el tratamiento de enfermedades tales como artritis reumatoide, epoc, cancer, entre otras.
CY1110860T1 (el) Αναστροφη μεταγραφαση τελομερασης πτηνου
UA101155C2 (ru) Модифицированный полипептид фактора vii (fvii) и его применение
IL294314A (en) Fibronectin based scaffold domain proteins that bind to myostatin
EA201101523A1 (ru) Способы лечения метаболических нарушений, использующие эпиметаболические переключатели, многоаспектные внутриклеточные молекулы или факторы влияния
EA201590910A1 (ru) Белки на основе структурного домена фибронектина, связывающие pcsk9
ATE489371T1 (de) Benzamidglucokinaseaktivatoren
EA200800667A1 (ru) Аптамеры, связывающие тромбин с высокой аффинностью
WO2012083302A3 (en) Compositions and methods for the treatment or prevention of human adenovirus-36 infection
CL2008000875A1 (es) Compuestos derivados de imidazolidin-2-ona; proceso de obtencion; composicion farmaceutica; y uso en el tratamiento y/o profilaxis de enfermedades tales como dislipidemia, diabetes, enfermedades inflamatorias, entre otras.